News - KRAS mutation - LARVOL VERI

Early fibrotic niches establish tumour-permissive microenvironments. (PubMed, Nature)

Disruption of the amphiregulin-EGFR axis prevents early niche formation and abrogates tumour initiation. Conservation of this programme in KRASG12D-inducible human alveolar organoids and early-stage lung adenocarcinoma tissues identifies epithelial-microenvironment communication as a therapeutically actionable vulnerability and suggests that intercepting niche formation may prevent progression to treatment-resistant disease.

1 day ago

Journal

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • EGFR mutation • KRAS G12D • KRAS G12

Evaluating Effective Biomarker Testing for Advanced Non-Small Cell Lung Cancer in US Community Oncology Practices. (PubMed, JCO Oncol Pract)

Although overall testing rates were high, more than 20% of patients lacked timely results to guide initial therapy. This critical gap may limit access to biomarker-directed treatment and highlights the need for streamlined diagnostic workflows and faster turnaround times to ensure optimal, evidence-based care in community oncology.

1 day ago

Journal • Biomarker testings

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)

KRAS mutation • EGFR mutation

Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC (ChiCTR2600121611)

P4, N=535, Recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital

2 days ago

New P4 trial • Real-world evidence

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset)

TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • ALK positive • RET fusion • ALK fusion • FGFR mutation • RET mutation • ROS1 fusion • MET mutation • RB1 mutation • NRG1 fusion • KRAS G12 • BRCA mutation

Ivesa (firmonertinib)

Alkaline Phosphatase, Placental Type (ALPP) Expression in KRAS-Mutant vs. Wild-Type Solid Tumors: A Diagnostic Study on Differential Expression and Clinical Correlation Based on Immunohistochemical Scoring (ChiCTR2600121328)

P=N/A, N=0, Shanghai East Hospital; Shanghai East Hospital

2 days ago

New trial

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=25, Terminated, Ningbo Newbay Technology Development Co., Ltd | N=120 --> 25 | Trial completion date: Sep 2026 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Sep 2025; Development change

2 days ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12C • KRAS G12

Lumakras (sotorasib)

Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass. (PubMed, Biochem J)

Together, these effects bypass intrinsic effector selectivity, allowing canonical RAS to co-opt effectors normally associated with other RAS subfamilies and broaden downstream signaling. This framework explains how inherent effector preferences govern normal signaling and how oncogenic mutations override these constraints to expand effector engagement in RAS-driven cancers.

3 days ago

Review • Journal

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • RAP1A (RAP1A, Member Of RAS Oncogene Family)

KRAS mutation • KRAS G12D • KRAS G12 • NRAS Q61 • NRAS G13 • KRAS Q61

EXaCT-2: an augmented and customizable oncology-focused whole exome sequencing platform. (PubMed, NPJ Precis Oncol)

In addition to mutations and SCNAs, the pipeline reports common cancer rearrangements, hematologic oncogenic viruses, BCR clonotypes, and global molecular metrics, such as tumor mutational burden (TMB) and microsatellite instability (MSI). Collectively, these results establish EXaCT-2 as a comprehensive platform for integrated cancer genome profiling.

3 days ago

Journal • Tumor mutational burden

KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)

KRAS mutation

AI-powered Deep Visual Proteomics reveals critical molecular transitions in pancreatic cancer precursors. (PubMed, Cancer Discov)

Mass spectrometry detected KRAS hotspot mutant peptides within incidental precursor lesions from cancer-free individuals. These findings demonstrate that molecular reprogramming precedes histological transformation, creating opportunities for earlier detection of lethal cancer.

3 days ago

Journal

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation

Stress Tested: Aging Rewires Tumors for Metastatic Spread Through Activation of the Integrated Stress Response. (PubMed, Cancer Res)

The identification of ATF4-driven ISR signaling as a mediator of metastasis highlights new therapeutic vulnerabilities, such as an acquired dependence on glutamine, particularly for older patients who comprise the majority of lung cancer cases. More broadly, this study underscores the need to incorporate aging biology into cancer models and therapeutic strategies, redefining how we conceptualize tumor progression across the lifespan.

3 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • ATF4 (Activating Transcription Factor 4)

KRAS mutation

Next-Generation Sequencing-Based Analysis of the Genetic Mutation Spectrum in Colorectal Cancer: A Large Single‑Center Study From Southeast China With Cross‑Population Comparison. (PubMed, Mol Carcinog)

This study demonstrates significant associations between specific gene mutations and distinct clinicopathological characteristics. The findings underscore the importance of integrating molecular profiling with conventional clinicopathological parameters for precise stratification.

3 days ago

Journal • Next-generation sequencing • MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability)

TP53 mutation • KRAS mutation • MSI-H/dMMR • PIK3CA mutation

Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer. (PubMed, Am J Surg Pathol)

Enteroblastic, hepatoid, and clear cell CRC demonstrate morphologic and IHC overlap, leading to interobserver variability in diagnosis. Given potential differences in clinical correlations and outcomes, more refined criteria are likely necessary.

3 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FBXW7 (F-Box And WD Repeat Domain Containing 7)

TP53 mutation • KRAS mutation

The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis. (PubMed, Clin Transl Med)

KRAS-mutant LUAD patients exhibit inferior pathological responses and survival after neoadjuvant immunotherapy compared to KRAS-wildtype patients. A CD4T_Treg_TNFRSF4 subset is enriched in non-responders, defining an immunosuppressive microenvironment. Responders are characterized by a synergistic network between Th1 cells and a novel exhausted-like B-cell (Bex) state. The balance between immunosuppressive Tregs and the Th1/Bex axis determines therapeutic efficacy in KRAS-mutant LUAD.

3 days ago

Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • TNFRSF4 (TNF Receptor Superfamily Member 4)

KRAS mutation • KRAS wild-type • RAS wild-type